Pubblicazioni

Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients

2021 - ANNALS OF HEMATOLOGY

Scalzulli, E.; Caocci, G.; Efficace, F.; Rizzo, L.; Colafigli, G.; Di Prima, A.; Pepe, S.; Fegatelli, D. A.; Carmosino, I.; Diverio, D.; Latagliata, R.; La Nasa, G.; Martelli, M.; Foa, R.; Breccia, M.

Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996

2021 - AMERICAN JOURNAL OF HEMATOLOGY

Piciocchi, A.; Messina, M.; Elia, L.; Vitale, A.; Soddu, S.; Testi, A. M.; Chiaretti, S.; Mancini, M.; Albano, F.; Spadano, A.; Krampera, M.; Bonifacio, M.; Cairoli, R.; Vetro, C.; Colella, F.; Ferrara, F.; Cimino, G.; Bassan, R.; Fazi, P.; Vignetti, M.

IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study

2021 - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Lawless, S; Sbianchi, G; Morris, C; Iacobelli, S; Bosman, P; Blaise, D; Remenyi, P; Byrne, Jl; Mayer, J; Apperley, J; Lund, J; Kobbe, G; Schaap, N; Isaksson, C; Lenhoff, S; Basak, G; Touzeau, C; Wilson, Kmo; Muniz, Sg; Scheid, C; Browne, P; Anagnostopoulos, A; Rambaldi, A; Jantunen, E; Kroger, N; Schonland, S; Yakoub-Agha, I; Garderet, L